Pagibaximab
From Infogalactic: the planetary knowledge core
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | staphylococcal lipoteichoic acid |
| Identifiers | |
| CAS Number | 595566-61-3  |
| ATC code | none |
| Chemical data | |
| Formula | C6462H9996N1728O2028S54 |
| Molecular mass | 146,072.36 g·mol−1 |
 (what is this?) (verify) |
|
Pagibaximab is a chimeric monoclonal antibody for the prevention of staphylococcal sepsis in infants with low birth weight. As of March 2010[update], it is undergoing Phase II/III clinical trials.[1][2]
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Clinical trial number NCT00646399 for "Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis" at ClinicalTrials.gov
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Monoclonal antibodies
- Antiinfective agent stubs
- Monoclonal antibody stubs
